An Open label, Multi-Centre, Randomized, Two-treatment, Multi dose, Parallel, Comparative Bioavailability Study of Bortezomib Injection 3.5 mg/0.2 ml and VELCADE 3.5 mg powder for solution for injection at a dose of 1.3 mg/m2 in Multiple Myeloma patients.

Shilpa Medicare Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 1 期
状态: 招募中
发起方: Shilpa Medicare Limited

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•i. Patient with histopathologically/ cytologically confirmed multiple myeloma.
•ii. Adult multiple myeloma patients weighing between 45 to 80 kg (both inclusive) who are naÃ¯ve and/or under treatment with Bortezomib or relapsed multiple myeloma (who have previously
•responded to treatment with Bortezomib either alone or in combination and who have relapsed at least 6 months after the prior therapy).
•iii. Patient with ECOG (Eastern Co-operative Oncology Group) performance status <= 2.
•iv. Patient with performance >=70% Karnofsky performance status scale.
•v. Patient must have adequate bone marrow (Hemoglobin levels >= 8.0 g/dL, ANC >=1500/mm3 and platelet count >= 1,00,000/mm3) prior to enrollment.
•vi. Patient must have adequate renal function (Serum creatinine <= 1.5 times of ULN). About 10% of Renal impaired patients will be enrolled who have Cockcroft-Gault creatinine clearance >= 30 ml/min with an upper limit of 89 ml/min.
•vii. Patient must have adequate hepatic function (Serum bilirubin <= 1.5 times of ULN and AST/ALT <= 2.0 times of ULN).
•viii. Subject who have no evidence of underlying disease which in the judgement of the investigator would not make the subject inappropriate for getting enrolled in the study (except multiple myeloma), during screening.
•ix. Patient and /or LAR or impartial witness able to give written informed consent for participation in the trial.
•x. Patient with life expectancy of at least four months.
•xi. In the opinion of the investigator, patient should be able to comply with study procedures.
•xii. Sexually active women, unless surgically sterile (at least 6 months prior to study drug administration) or postmenopausal (females who have had a natural menopause for at least 24 consecutive months), must agree to use two effective methods of avoiding pregnancy for at least 4 weeks prior to study drug administration, during study and up to 60 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician.
•xiii. In case of male patients: Male patients must agree to practice complete abstinence or agree to use a condom during sexual contact with a female even if they have had a successful vasectomy.
•It is investigatorâ??s responsibility to ensure that above points regarding an effective method of avoiding pregnancy are discussed with patient in detail and patient agreed for this and it is documented in source document. The investigator should ensure that the patient is using an effective method of avoiding pregnancy as per protocol.

排除标准

•i. Known hypersensitivity to Bortezomib or to any of the excipients, Cyclophosphamide and Dexamethasone.
•ii. If the patient had undergone prior surgery, chemotherapy, or other anti- cancer therapy within 4 weeks (28 days), thalidomide and/or lenalidomide within 2 weeks prior to dosing in the study.
•iii. Patient with known human immunodeficiency virus (HIV) infection.
•iv. A positive hepatitis screen including HBSAg and HCV antibodies.
•v. Use of any recreational drugs or history of drug addiction.
•vi. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 milliseconds (ms)) or history of
•additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) or use of concomitant medications that prolong the QT/QTc interval.
•vii. History of venous thromboembolism or disease that aggravate risk for thromboembolism.
•viii. Patient taking concurrent medications at entry that may act as inhibitors/inducers of CYP3A4 CYP2C19 and CYP1A2.
•ix. Patient with cardiac disease known and clinically significant grade 2 neuropathy, pulmonary, hepatic, gastrointestinal, endocrine, immunologic, dermatological, musculo-skeletal, psychiatric, neurological, proven amyloidosis and secondary malignancy.
•x. Patient with a history of difficulty in donating blood or difficulty in accessibility of veins.
•xi. Patient participated in any drug intervention study and donated blood within 90 days prior to the current study.
•xii. Female patients with pregnancy or breast-feeding.
•xiii. Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study treatment.

研究者

发起方

Shilpa Medicare Limited

相似试验

已完成

不适用

Bioavailability study of Bortezomib for Injection 3.5 mg/vial in patients with Multiple Myeloma

CTRI/2019/03/018107Shilpa Medicare Limited6

进行中（未招募）

不适用

Bioequivalence (BE) study of Paclitaxel 100mg/vial with ABRAXANE® 100mg/vial in subject with metastatic Breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy.

CTRI/2024/03/064383Anbison Lab. Co., Ltd.

尚未招募

不适用

Bioequivalence study of doxorubicin hydrochloride liposome injection 2mg/mL in ovarian cancer subjects under fasting conditions.

CTRI/2020/05/025245Shanghai Jingfeng Pharmaceuticals Group Co Ltd China

招募中

不适用

Bioequivalence Study of Leuprolide Depot Injection 7.5 mg of with LUPRON Depot (leuprolide acetate for depot suspension) 7.5 mg in subjects with locally advanced and/or metastatic prostate cancer undergoing initial therapy.

CTRI/2022/04/041602American Regent Inc

尚未招募

不适用

A bioequivalance study comparing Tobradex eye drops of Alcon pharma with study medication with same combination of Cipla in aqueous humor of patients undergoing cataract surgery.

CTRI/2015/10/006326Cipla Ltd36